Arixtra approved for superficial-vein thrombosis

Arixtra (fondaparinux) has been approved for the treatment of acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis (DVT).

Treatment should be initiated as soon as possible following diagnosis and after exclusion of concomitant DVT or superficial-vein thrombosis within 3cm of the sapheno-femoral junction.

Therapy with Arixtra should be continued for ?30—45 days. Patients may self inject if willing ?and able to do so, following clear instruction by their physician.

View Arixtra drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Macrolide prescribing in pregnancy linked to risk of birth defects

Macrolide prescribing in pregnancy linked to risk of birth defects

Researchers have called for caution when prescribing...

NICE overturns advice to increase steroid dose in children with asthma

NICE overturns advice to increase steroid dose in children with asthma

NICE has withdrawn its recommendation to quadruple...

New antibiotic guidance for leg ulcer infection

New antibiotic guidance for leg ulcer infection

NICE has issued guidance on antibiotic choices and...